Payors Will Help Diagnostics Eclipse Drugs In New Medicine Age – Investor
This article was originally published in The Gray Sheet
Medical diagnostics' profitability will supersede that of drugs in an age of personalized medicine, with the payor community driving the change, predicted Steven Burrill, CEO of venture capital and merchant banking firm Burrill & Company
You may also be interested in...
Diagnostic firms are gaining favor in venture capitalist circles as healthcare moves toward targeted medicine, according to BioAdvance Ventures Managing Director Gary Kurtzman, MD
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.